Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-557-531"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-557-531"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-557-5622
lpv:speaker	lp:Radvilė Morkūnaitė-mikulėnienė2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 member; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; REGI (2012-01-19--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 member; ENVI (2012-01-19--2014-06-30)3 unknown; Tėvynės sąjunga - Lietuvos krikščionys demokratai (2009-07-14--2014-06-30)3
lpv:translated text	"I voted in favour of the conclusion of an agreement between the EU and Israel which is undoubtedly beneficial for EU consumers because it will help to significantly reduce the prices of imported pharmaceuticals and make generic medicines more accessible to European Union citizens. This agreement, which is to be concluded under the Association Agreement and will be a protocol to it, will apply to the same extent as provided for in Article 83 of the Association Agreement. The Commission is committed to monitoring the territorial dimension. At the same time I refer to the clarification of Conformity Assessment and Acceptance of Industrial Products and the origin of products provided to the European Parliament by the Commission during the discussion on 3 July 2012. In terms of coherence it is true that some other EU partners are in a similar situation but this has a limited impact on the development of trade relations between the EU and them and bilateral trade is encouraged, with the EU choosing to have an effect through greater involvement."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph